4D Molecular Therapeutics(FDMT) - 2025 Q4 - Annual Results

Exhibit 99.1 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2025 financial results, provided operational highlights and ou ...